NCT05391750 2026-02-17Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple MyelomaEmory UniversityPhase 1 Active not recruiting7 enrolled
NCT06042725 2025-12-24MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaMayo ClinicPhase 1 Recruiting100 enrolled
NCT05853965 2025-03-30BELI(E)VEUniversitätsklinikum Hamburg-EppendorfPhase 1/2 Recruiting45 enrolled
NCT03399539 2024-11-04Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple MyelomaMayo ClinicPhase 1 Completed8 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled